• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Hansoh Pharmaceutical Group (SEHK:3692) Moved Today, What Is Behind The Attention?

    Simply Wall St·10/23/2026 20:28:43
    Listen to the news

    Hansoh Pharmaceutical Group (SEHK:3692) just signed a wide-ranging collaboration and license agreement with Roche covering multiple Antibody Drug Conjugate programs, anchored by a US$400 million upfront payment and substantial milestone potential.

    Hansoh Pharmaceutical Group has enjoyed a sharp bump in interest, with a 1-day share price return of 3.58% taking the stock to HK$33.0, following a softer 30-day share price decline of 5.55% and a year-to-date share price return down 9.44%.

    Scan how the Hansoh Pharmaceutical Group news compares to other fast-moving healthcare opportunities by reviewing our hand picked 126 healthcare AI stocks alongside this ADC partnership.

    Bulls see Hansoh Pharmaceutical Group securing a rare ADC partnership and fresh cash inflow, while bears focus on a weak year to date share performance. Which side does the valuation actually lean toward as things stand?

    Preferred P/E of 25.5x: Is it justified for Hansoh Pharmaceutical Group?

    Hansoh Pharmaceutical Group trades on a P/E of 25.5x, which prices the latest HK$33.0 close at a premium to both its peers and the broader Hong Kong pharmaceuticals sector.

    The P/E ratio compares the share price to earnings per share. For a drug maker like Hansoh Pharmaceutical Group, it is often used as a quick read on how much investors are paying today for each unit of profit, especially when the business is already profitable and generating meaningful net income.

    Hansoh Pharmaceutical Group has earnings that grew 39.7% over the past year and 20.5% per year over five years, alongside net profit margins currently at 42% compared with 36.3% last year. A higher P/E can reflect that kind of profit momentum, although our data also flags a high level of non cash earnings, which means some of those profits may be more accounting driven than pure cash generation. The stock is trading at a 34.9% discount to the SWS DCF based fair value estimate of HK$50.72, so the premium P/E multiple sits alongside a DCF view that points to undervaluation on future cash flows.

    Compared with the Hong Kong pharmaceuticals industry average P/E of 13.3x and a fair P/E ratio estimate of 24.5x for Hansoh Pharmaceutical Group, the current 25.5x level looks clearly richer than sector peers and slightly above the level the regression based fair ratio suggests the market could gravitate toward.

    Explore the SWS fair ratio for Hansoh Pharmaceutical Group.

    Result: Price-to-earnings of 25.5x (OVERVALUED)

    Still, the narrative around Hansoh Pharmaceutical Group could be knocked off course if ADC milestones disappoint or if competition in its China focus areas intensifies.

    Find out about the key risks to this Hansoh Pharmaceutical Group narrative.

    Another View on Hansoh Pharmaceutical Group’s Value

    The P/E screen paints Hansoh Pharmaceutical Group as expensive at 25.5x, yet the SWS DCF model tells a different story. On that cash flow view, the estimated fair value sits at HK$50.72, which is 34.9% above the current HK$33.0 share price and points to undervaluation instead.

    Two tools, two outcomes. If earnings multiples suggest a rich tag but the SWS DCF model flags upside based on future cash flows, which lens should carry more weight for you right now: the headline multiple or the longer term cash generation potential.

    Look into how the SWS DCF model arrives at its fair value.

    3692 Discounted Cash Flow as at Oct 2026
    3692 Discounted Cash Flow as at Oct 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 201 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Mixed signals across Hansoh Pharmaceutical Group can make the story feel messy, which is exactly why you should examine the underlying data yourself and move quickly from headlines to your own conviction. To weigh the upside potential against the open questions, start with our breakdown of 4 key rewards and 1 important warning sign.

    Hunting for more investment ideas beyond Hansoh Pharmaceutical Group?

    If Hansoh Pharmaceutical Group has your attention, do not stop here. Broaden your watchlist with fresh ideas that line up with your own risk and return preferences.